Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 3
Submit an article Journal homepage
1,323
Views
110
CrossRef citations to date
0
Altmetric
Brief Reviews

Neuroprotective properties of GLP-1: theoretical and practical applications

Jens Juul Holst Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]
,
Remy Burcelin Rangueil Institute of Molecular Medicine, Toulouse, France
&
Esther Nathanson Watermeadow Medical USA, New York, NY, USA
Pages 547-558 | Accepted 16 Dec 2010, Published online: 12 Jan 2011

Citations (110)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Yiwen Cheng, Jiaming Liu & Zongxin Ling. (2022) Short-chain fatty acids-producing probiotics: A novel source of psychobiotics. Critical Reviews in Food Science and Nutrition 62:28, pages 7929-7959.
Read now
Xiaoyan Yang, Peng Feng, Rong Ji, Yiqing Ren, Wenshi Wei & Christian Hölscher. (2022) Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease. Expert Opinion on Therapeutic Targets 26:5, pages 445-460.
Read now
Antonella Tramutola, Andrea Arena, Chiara Cini, D. Allan Butterfield & Eugenio Barone. (2017) Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology. Expert Review of Neurotherapeutics 17:1, pages 59-75.
Read now
Tse-Ying Chen & Ching-Jung Hsieh. (2014) Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 205-215.
Read now
Giuseppina Opinto, Annalisa Natalicchio & Piero Marchetti. (2013) Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Archives of Physiology and Biochemistry 119:4, pages 170-178.
Read now
Christine Wallrapp, Eric Thoenes, Frank Thürmer, Anette Jork, Moustapha Kassem & Peter Geigle. (2013) Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells. Journal of Microencapsulation 30:4, pages 315-324.
Read now
Alan J Garber. (2012) Novel GLP-1 receptor agonists for diabetes. Expert Opinion on Investigational Drugs 21:1, pages 45-57.
Read now
Ann Mosegaard Bak, Lærke Egefjord, Michael Gejl, Charlotte Steffensen, Chalotte Willemann Stecher, Kamille Smidt, Birgitte Brock & Jørgen Rungby. (2011) Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opinion on Therapeutic Targets 15:10, pages 1153-1162.
Read now

Articles from other publishers (102)

Daniel H. Cooper, Ranuk Ramachandra, Felicia Ceban, Joshua D. Di Vincenzo, Taeho Greg Rhee, Rodrigo B. Mansur, Kayla M. Teopiz, Hartej Gill, Roger Ho, Bing Cao, Leanna M.W. Lui, Muhammad Youshay Jawad, Juliet Arsenault, Gia Han Le, Diluk Ramachandra, Ziji Guo & Roger S. McIntyre. (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. Journal of Psychiatric Research 164, pages 80-89.
Crossref
Wenhui Lei, Yiwen Cheng, Jie Gao, Xia Liu, Li Shao, Qingming Kong, Nengneng Zheng, Zongxin Ling & Weiming Hu. (2023) Akkermansia muciniphila in neuropsychiatric disorders: friend or foe?. Frontiers in Cellular and Infection Microbiology 13.
Crossref
Vyron Gorgogietas, Bahareh Rajaei, Chae Heeyoung, Bruno J. Santacreu, Sandra Marín-Cañas, Paraskevi Salpea, Toshiaki Sawatani, Anyishai Musuaya, María N. Arroyo, Cristina Moreno-Castro, Khadija Benabdallah, Celine Demarez, Sanna Toivonen, Cristina Cosentino, Nathalie Pachera, Maria Lytrivi, Ying Cai, Lode Carnel, Cris Brown, Fumihiko Urano, Piero Marchetti, Patrick Gilon, Decio L. Eizirik, Miriam Cnop & Mariana Igoillo-Esteve. (2023) GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models. Diabetologia 66:7, pages 1306-1321.
Crossref
Haiyang Du, Xiaoyu Meng, Yu Yao & Jun Xu. (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Frontiers in Endocrinology 13.
Crossref
Giulia Monti, Diana Gomes Moreira, Mette Richner, Henricus Antonius Maria Mutsaers, Nelson Ferreira & Asad Jan. (2022) GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells 11:13, pages 2023.
Crossref
Changliang Zhu, Hailiang Li, Xuerui Kong, Yezhong Wang, Tao Sun & Feng Wang. (2022) Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. Frontiers in Pharmacology 13.
Crossref
KinjalV Abhangi & JigneshkumarIshwarlal Patel. (2022) Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson's disease. Indian Journal of Pharmacology 54:1, pages 46.
Crossref
Sweta Shah, Marc Marie Dooms, Sofia Amaral-Garcia & Mariana Igoillo-Esteve. (2021) Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Frontiers in Pharmacology 12.
Crossref
Jie Luo, Hongfei Zhang, Jiachen Lu, ChaoLin Ma & Tingtao Chen. (2021) Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e -GLP-1 in monkey model. Synthetic and Systems Biotechnology 6:4, pages 272-282.
Crossref
A Young Sim, Sumit Barua, Jong Youl Kim, Yong-ho Lee & Jong Eun Lee. (2021) Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. Frontiers in Neuroscience 15.
Crossref
Changliang Zhu, Hong Tao, Shikuo Rong, Lifei Xiao, Xinxiao Li, Shucai Jiang, Baorui Guo, Lei Wang, Jiangwei Ding, Caibing Gao, Haigang Chang, Tao Sun & Feng Wang. (2021) Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice. Frontiers in Pharmacology 12.
Crossref
Michael A. Nauck, Daniel R. Quast, Jakob Wefers & Juris J. Meier. (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism 46, pages 101102.
Crossref
Sjoukje Nutma, Joost le Feber & Jeannette Hofmeijer. (2021) Neuroprotective Treatment of Postanoxic Encephalopathy: A Review of Clinical Evidence. Frontiers in Neurology 12.
Crossref
Keshav Mehta, Tapan Behl, Arun Kumar, M. Sahab Uddin, Gokhan Zengin & Sandeep Arora. (2021) Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions. Current Protein & Peptide Science 22:1, pages 4-18.
Crossref
Temitope Isaac Adelusi, Gbemisola Rebecca Akinbolaji, Xiaoxing Yin, Kehinde Sulaimon Ayinde & Olamide Tosin Olaoba. (2021) Neurotrophic, anti-neuroinflammatory, and redox balance mechanisms of chalcones. European Journal of Pharmacology 891, pages 173695.
Crossref
Federica Ferrari, Antonio Moretti & Roberto Federico Villa. (2020) The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs. Pharmacological Research 160, pages 105018.
Crossref
Hugo Ramos, Patricia Bogdanov, Joel Sampedro, Jordi Huerta, Rafael Simó & Cristina Hernández. (2020) Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress. Antioxidants 9:9, pages 846.
Crossref
Gang Zhang, Samuel Kim, Xiaohuan Gu, Shan Ping Yu & Ling Wei. (2019) DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects. Neuroscience Bulletin 36:4, pages 407-418.
Crossref
Ioanna Markaki, Kristian Winther, Sergiu-Bogdan Catrina & Per Svenningsson. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases 91 112 .
Christina Brock, Christian Stevns Hansen, Jesper Karmisholt, Holger Jon Møller, Anne Juhl, Adam Donald Farmer, Asbjørn Mohr Drewes, Sam Riahi, Hans Henrik Lervang, Poul Erik Jakobsen & Birgitte Brock. (2019) Liraglutide treatment reduced interleukin‐6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. British Journal of Clinical Pharmacology 85:11, pages 2512-2523.
Crossref
Marcelo Florencio Passos Silva, Patricia Lucio Alves, Rafaela Fadoni Alponti, Paulo Flavio Silveira & Fernando Maurício Francis Abdalla. (2019) Effects of obesity induced by high-calorie diet and its treatment with exenatide on muscarinic acetylcholine receptors in rat hippocampus. Biochemical Pharmacology 169, pages 113630.
Crossref
Xin Fang, Puyuan Tian, Xiaoxiao Zhao, Chunling Jiang & Tingtao Chen. (2019) Neuroprotective effects of an engineered commensal bacterium in the 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine Parkinson disease mouse model via producing glucagon‐like peptide‐1. Journal of Neurochemistry 150:4, pages 441-452.
Crossref
Yongjian Zhou, Zhe Li, Xuezhao Cao, Hong Ma, Paul F. White, Xiaohan Xu, Yanhua Jiang, Xijia Sun & Yong Cui. (2019) Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy. Brain Research 1706, pages 116-124.
Crossref
Pallavi Rane, Deepaneeta Sarmah, Shashikala Bhute, Harpreet Kaur, Avirag Goswami, Kiran Kalia, Anupom Borah, Kunjan R. Dave, Nutan Sharma & Pallab Bhattacharya. (2018) Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums. ACS Chemical Neuroscience 10:1, pages 44-57.
Crossref
Annayya R. Aroor, Camila Manrique-Acevedo & Vincent G. DeMarco. (2018) The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovascular Diabetology 17:1.
Crossref
Sung Woo Park, Rodrigo B. Mansur, Yena Lee, Jae-Hon Lee, Mi Kyoung Seo, Ah Jeong Choi, Roger S. McIntyre & Jung Goo Lee. (2018) Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions. Frontiers in Neuroscience 12.
Crossref
Tingtao Chen, Puyuan Tian, Zhixiang Huang, Xiaoxiao Zhao, Huan Wang, Chaofei Xia, Le Wang & Hua Wei. (2018) Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1. Applied Microbiology and Biotechnology 102:17, pages 7565-7575.
Crossref
Ilijana Babic, Ashleigh Gorak, Martin Engel, Dominic Sellers, Paul Else, Ashleigh L Osborne, Nagesh Pai, Xu-Feng Huang, Jessica Nealon & Katrina Weston-Green. (2018) Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. Journal of Psychopharmacology 32:5, pages 578-590.
Crossref
Natalia Andrea Rojas-Henao & Elkyn Johan Granados-Vega. (2018) Glucagon like peptide 1 receptor agonists: a therapy for diabetes management. Ces Medicina 32:1, pages 23-30.
Crossref
Jingjing Tai, Weizhen Liu, Yanwei Li, Lin Li & Christian Hölscher. (2018) Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease. Brain Research 1678, pages 64-74.
Crossref
Omar Babateen, Sergiy V. Korol, Zhe Jin, Amol K. Bhandage, Aikeremu Ahemaiti & Bryndis Birnir. (2017) Liraglutide modulates GABAergic signaling in rat hippocampal CA3 pyramidal neurons predominantly by presynaptic mechanism. BMC Pharmacology and Toxicology 18:1.
Crossref
Jonathan Gotfried, Stephen Priest & Ron Schey. (2017) Diabetes and the Small Intestine. Current Treatment Options in Gastroenterology 15:4, pages 490-507.
Crossref
Choon Bae & Juhyun Song. (2017) The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain. International Journal of Molecular Sciences 18:11, pages 2493.
Crossref
Soojin Kim, Jaewon Jeong, Hye-Seon Jung, Bokyung Kim, Ye-Eun Kim, Da-Sol Lim, So-Dam Kim & Yun Seon Song. (2017) Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke. Experimental Neurobiology 26:4, pages 227-239.
Crossref
Hari B. Keshava, Ashkan Mowla, Leslie J. Heinberg, Philip R. Schauer, Stacy A. Brethauer & Ali Aminian. (2017) Bariatric surgery may reduce the risk of Alzheimer’s diseases through GLP-1 mediated neuroprotective effects. Medical Hypotheses 104, pages 4-9.
Crossref
Andrew J. Krentz & Angelo Scuteri. 2017. Diabetes in Old Age. Diabetes in Old Age 177 212 .
Giovanna Muscogiuri, Ralph A. DeFronzo, Amalia Gastaldelli & Jens J. Holst. (2017) Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends in Endocrinology & Metabolism 28:2, pages 88-103.
Crossref
Shuang-Shuang Zhang, Zhou Wu, Zhen Zhang, Zhou-Yi Xiong, Hong Chen & Qiao-Bing Huang. (2017) Glucagon-like peptide-1 inhibits the receptor for advanced glycation endproducts to prevent podocyte apoptosis induced by advanced oxidative protein products. Biochemical and Biophysical Research Communications 482:4, pages 1413-1419.
Crossref
Sebastian WibergChristian HassagerHenrik SchmidtJakob Hartvig ThomsenMartin FrydlandMatias Greve LindholmDan Eik HøfstenThomas EngstrømLars KøberJacob Eifer MøllerJesper Kjaergaard. (2016) Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest. Circulation 134:25, pages 2115-2124.
Crossref
Sebastian Wiberg, Christian Hassager, Jakob Hartvig Thomsen, Martin Frydland, Dan Eik Høfsten, Thomas Engstrøm, Lars Køber, Henrik Schmidt, Jacob Eifer Møller & Jesper Kjaergaard. (2016) GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial. Trials 17:1.
Crossref
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref
D. Athauda & T. Foltynie. (2016) Insulin resistance and Parkinson’s disease: A new target for disease modification?. Progress in Neurobiology 145-146, pages 98-120.
Crossref
Francesca D’Addio & Paolo Fiorina. (2016) Type 1 Diabetes and Dysfunctional Intestinal Homeostasis. Trends in Endocrinology & Metabolism 27:7, pages 493-503.
Crossref
Dilan Athauda & Thomas Foltynie. (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discovery Today 21:5, pages 802-818.
Crossref
Douglas J. Taatjes & Jürgen Roth. (2016) The Histochemistry and Cell Biology omnium-gatherum: the year 2015 in review. Histochemistry and Cell Biology 145:3, pages 239-274.
Crossref
Hans Gregersen, Donghua Liao, Anne Mohr Drewes, Asbjørn Mohr Drewes & Jingbo Zhao. (2016) Ravages of Diabetes on Gastrointestinal Sensory-Motor Function: Implications for Pathophysiology and Treatment. Current Gastroenterology Reports 18:2.
Crossref
Timur Dmitrievich Vlasov, Anna Vladimirovna Simanenkova, Svetlana Vladimirovna Dora & Evgeniy Vladimirovich Shlyakhto. (2016) Mechanisms of neuroprotective action of incretin mimetics. Diabetes mellitus 19:1, pages 16-23.
Crossref
Cristina Hernández, Patricia Bogdanov, Lidia Corraliza, Marta García-Ramírez, Cristina Solà-Adell, José A. Arranz, Ana I. Arroba, Angela M. Valverde & Rafael Simó. (2016) Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes 65:1, pages 172-187.
Crossref
Swati Jain & Bhupesh Sharma. (2015) Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiology & Behavior 152, pages 182-193.
Crossref
Alexander O Shpakov, Kira V Derkach & Lev M Berstein. (2015) Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Science OA 1:3.
Crossref
Viktor József Horváth, Zsuzsanna Putz, Ferenc Izbéki, Anna Erzsébet Körei, László Gerő, Csaba Lengyel, Péter Kempler & Tamás Várkonyi. (2015) Diabetes-Related Dysfunction of the Small Intestine and the Colon: Focus on Motility. Current Diabetes Reports 15:11.
Crossref
Masami Tsukamoto, Naoko Niimi, Kazunori Sango, Shizuka Takaku, Yasushi Kanazawa & Kazunori Utsunomiya. (2015) Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA. Histochemistry and Cell Biology 144:3, pages 249-259.
Crossref
Donna Ryan & Andres Acosta. (2015) GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond . Obesity 23:6, pages 1119-1129.
Crossref
Mariana Igoillo-Esteve, Ewa Gurgul-Convey, Amélie Hu, Laila Romagueira Bichara Dos Santos, Baroj Abdulkarim, Satyan Chintawar, Lorella Marselli, Piero Marchetti, Jean-Christophe Jonas, Décio L. Eizirik, Massimo Pandolfo & Miriam Cnop. (2015) Unveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich's ataxia. Human Molecular Genetics 24:8, pages 2274-2286.
Crossref
Partha Pratim Chakraborty, Sayantan Ray, Rana Bhattacharjee, Sujoy Ghosh, Pradip Mukhopadhyay, Satinath Mukhopadhyay & Subhankar Chowdhury. (2015) First Presentation of Diabetes as Diabetic Ketoacidosis in a Case of Friedreich’s Ataxia. Clinical Diabetes 33:2, pages 84-86.
Crossref
V. A. Gault, R. Lennox & P. R. Flatt. (2015) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes, Obesity and Metabolism 17:4, pages 403-413.
Crossref
Jakob Hakon, Karsten Ruscher, Bertil Romner & Gregor Tomasevic. (2015) Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury. PLOS ONE 10:3, pages e0120074.
Crossref
Yuichi Makino, Yukihiro Fujita & Masakazu Haneda. (2015) Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Current Opinion in Nephrology and Hypertension 24:1, pages 67-73.
Crossref
M. Giovanna Trivella, Alessandro Tonacci, Lucia Billeci, Vincenzo Gemignani, Amalia Gastaldelli & Angelo Gemignani. 2015. Ambient Assisted Living. Ambient Assisted Living 407 417 .
Rachael Lennox, Peter R. Flatt & Victor A. Gault. (2014) Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides 61, pages 38-47.
Crossref
Rachael Lennox, David W. Porter, Peter R. Flatt, Christian Holscher, Nigel Irwin & Victor A. Gault. (2014) Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology 86, pages 22-30.
Crossref
Julie A. Lovshin & Bernard Zinman. (2014) Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. Canadian Journal of Diabetes 38:5, pages 364-371.
Crossref
Kazunari Sekiyama, Yoshiki Takamatsu, Masaaki Waragai & Makoto Hashimoto. (2014) Role of genomics in translational research for Parkinson’s disease. Biochemical and Biophysical Research Communications 452:2, pages 226-235.
Crossref
Jeppe Skov. (2014) Effects of GLP-1 in the Kidney. Reviews in Endocrine and Metabolic Disorders 15:3, pages 197-207.
Crossref
Jan Hansen, Birgitte Brock, Hans Erik Bøtker, Albert Gjedde, Jørgen Rungby & Michael Gejl. (2014) Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited. Reviews in Endocrine and Metabolic Disorders 15:3, pages 219-231.
Crossref
Vladimer Darsalia, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm & Cesare Patrone. (2014) GLP-1R activation for the treatment of stroke: Updating and future perspectives. Reviews in Endocrine and Metabolic Disorders 15:3, pages 233-242.
Crossref
Annayya R. Aroor, James R. Sowers, Guanghong Jia & Vincent G. DeMarco. (2014) Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. American Journal of Physiology-Heart and Circulatory Physiology 307:4, pages H477-H492.
Crossref
Michael Gejl, Jørgen Rungby, Birgitte Brock & Albert Gjedde. (2014) At the Centennial of Michaelis and Menten, Competing Michaelis-Menten Steps Explain Effect of GLP-1 on Blood-Brain Transfer and Metabolism of Glucose. Basic & Clinical Pharmacology & Toxicology 115:2, pages 162-171.
Crossref
Vladimer Darsalia, Anna Olverling, Martin Larsson, Shiva Mansouri, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm & Cesare Patrone. (2014) Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regulatory Peptides 190-191, pages 25-31.
Crossref
Eirik Søfteland, Christina Brock, Jens B. Frøkjær, Jan Brøgger, László Madácsy, Odd H. Gilja, Lars Arendt-Nielsen, Magnus Simrén, Asbjørn M. Drewes & Georg Dimcevski. (2014) Association between visceral, cardiac and sensorimotor polyneuropathies in diabetes mellitus. Journal of Diabetes and its Complications 28:3, pages 370-377.
Crossref
Rémy BurcelinPierre Gourdy & Stéphane Dalle. (2014) GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action. Physiology 29:2, pages 108-121.
Crossref
Young Min ChoYukihiro FujitaTimothy J. Kieffer. (2014) Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond. Annual Review of Physiology 76:1, pages 535-559.
Crossref
Nigel H. Greig, David Tweedie, Lital Rachmany, Yazhou Li, Vardit Rubovitch, Shaul Schreiber, Yung-Hsiao Chiang, Barry J. Hoffer, Jonathan Miller, Debomoy K. Lahiri, Kumar Sambamurti, Robert E. Becker & Chaim G. Pick. (2014) Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimer's & Dementia 10:1S.
Crossref
Dema Najem, Michelle Bamji-Mirza, Nina Chang, Qing Yan Liu & Wandong Zhang. (2014) Insulin resistance, neuroinflammation, and Alzheimer’s disease. Reviews in the Neurosciences 25:4.
Crossref
Katharine Eakin, Yazhou Li, Yung-Hsiao Chiang, Barry J. Hoffer, Hilary Rosenheim, Nigel H. Greig & Jonathan P. Miller. (2013) Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats. PLoS ONE 8:12, pages e82016.
Crossref
Christina Brock, Eirik Søfteland, Veronica Gunterberg, Jens Brøndum Frøkjær, Dina Lelic, Birgitte Brock, Georg Dimcevski, Hans Gregersen, Magnus Simrén & Asbjørn Mohr Drewes. (2013) Diabetic Autonomic Neuropathy Affects Symptom Generation and Brain-Gut Axis. Diabetes Care 36:11, pages 3698-3705.
Crossref
Ian A. Clark & Bryce Vissel. (2013) Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochemical Pharmacology 86:7, pages 862-871.
Crossref
Alexander O. Shpakov & Kira V. Derkach. (2013) The Functional State of Hormone-Sensitive Adenylyl Cyclase Signaling System in Diabetes Mellitus. Journal of Signal Transduction 2013, pages 1-16.
Crossref
Hutan Ashrafian, Leanne Harling, Ara Darzi & Thanos Athanasiou. (2013) Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?. Metabolic Brain Disease 28:3, pages 341-353.
Crossref
Miriam Cnop, Hindrik Mulder & Mariana Igoillo-Esteve. (2013) Diabetes in Friedreich Ataxia. Journal of Neurochemistry 126, pages 94-102.
Crossref
Baptist Gallwitz. (2013) Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes. Diabetes Management 3:4, pages 323-331.
Crossref
Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones & Michael Horowitz. (2013) Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides 44, pages 75-86.
Crossref
B. Gallwitz. (2013) Inkretinbasierte TherapienIncretin-based therapies. Der Diabetologe 9:4, pages 283-288.
Crossref
H. Pintana, N. Apaijai, N. Chattipakorn & S. C. Chattipakorn. (2013) DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. Journal of Endocrinology 218:1, pages 1-11.
Crossref
A. O. Shpakov & K. V. Derkach. (2013) Peptidergic signaling brain systems in diabetes mellitus. Cell and Tissue Biology 7:3, pages 212-220.
Crossref
Richard P. Shannon. (2013) DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?. Diabetes 62:4, pages 1029-1031.
Crossref
R. Burcelin & B. Thorens. (2013) Incretins: What is known, new and controversial in 2013?. Diabetes & Metabolism 39:2, pages 89-93.
Crossref
A.I. Duarte, E. Candeias, S.C. Correia, R.X. Santos, C. Carvalho, S. Cardoso, A. Plácido, M.S. Santos, C.R. Oliveira & P.I. Moreira. (2013) Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1832:4, pages 527-541.
Crossref
Mark P Plummer, Juris J Meier & Adam M Deane. (2013) The gut-brain axis in the critically ill: Is glucagon-like peptide-1 protective in neurocritical care?. Critical Care 17:4, pages 163.
Crossref
J. J. Holst & T. Vilsbøll. (2013) Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism 15:1, pages 3-14.
Crossref
David Tweedie, Lital Rachmany, Vardit Rubovitch, Elin Lehrmann, Yongqing Zhang, Kevin G. Becker, Evelyn Perez, Jonathan Miller, Barry J. Hoffer, Nigel. H. Greig & Chaim G. Pick. (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Experimental Neurology 239, pages 170-182.
Crossref
Jens Juul Holst, Carolyn F. Deacon Bolette Hartmann & Jens Pedersen. 2013. Handbook of Biologically Active Peptides. Handbook of Biologically Active Peptides 1241 1250 .
Bjørn H Ebdrup, Filip K Knop, Pelle L Ishøy, Egill Rostrup, Birgitte Fagerlund, Henrik Lublin & Birte Glenthøj. (2012) Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Medicine 10:1.
Crossref
Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho & Bryce Vissel. (2012) Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales. Pharmacological Reviews 64:4, pages 1004-1026.
Crossref
M.S. Fineman, B.B. Cirincione, D. Maggs & M. Diamant. (2012) GLP‐1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism 14:8, pages 675-688.
Crossref
Jonathan D Roth, Mary R Erickson, Steve Chen & David G Parkes. (2012) GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. British Journal of Pharmacology 166:1, pages 121-136.
Crossref
Vladimer Darsalia, Shiva Mansouri, Henrik Ortsäter, Anna Olverling, Nino Nozadze, Camilla Kappe, Kerstin Iverfeldt, Linda M. Tracy, Nina Grankvist, Åke Sjöholm & Cesare Patrone. (2012) Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clinical Science 122:10, pages 473-483.
Crossref
Yazhou Li, Srinivasulu Chigurupati, Harold W. Holloway, Mohamed Mughal, David Tweedie, Daniel A. Bruestle, Mark P. Mattson, Yun Wang, Brandon K. Harvey, Balmiki Ray, Debomoy K. Lahiri & Nigel H. Greig. (2012) Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS ONE 7:2, pages e32008.
Crossref
Liza K. Phillips & Johannes B. Prins. (2011) Update on incretin hormones. Annals of the New York Academy of Sciences 1243:1, pages E55-E74.
Crossref
Mukesh Punjabi, Myrtha Arnold, Nori Geary, Wolfgang Langhans & Gustavo Pacheco-López. (2011) Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation. Physiology & Behavior 105:1, pages 71-76.
Crossref
A. E. Hogan, A. M. Tobin, T. Ahern, M. A. Corrigan, G. Gaoatswe, R. Jackson, V. O’Reilly, L. Lynch, D. G. Doherty, P. N. Moynagh, B. Kirby, J. O’Connell & D. O’Shea. (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54:11, pages 2745-2754.
Crossref
Victor A. GaultBarry D. KerrPatrick HarriottPeter R. Flatt. (2011) Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clinical Science 121:3, pages 107-117.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.